Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Brief Summary: The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).


Options:
A: Arm Label: obinutuzumab + chlorambucil (GClb); Type: EXPERIMENTAL; Interventions: Drug: obinutuzumab, Drug: chlorambucil | Arm Label: rituximab + chlorambucil (RClb); Type: ACTIVE_COMPARATOR; Interventions: Drug: rituximab, Drug: chlorambucil | Arm Label: Chlorambucil (Clb); Type: ACTIVE_COMPARATOR; Interventions: Drug: chlorambucil | Intervention Type: DRUG; Name: obinutuzumab; Assigned to Arm(s): obinutuzumab + chlorambucil (GClb) | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): rituximab + chlorambucil (RClb) | Intervention Type: DRUG; Name: chlorambucil; Assigned to Arm(s): Chlorambucil (Clb), obinutuzumab + chlorambucil (GClb), rituximab + chlorambucil (RClb)
B: Arm Label: Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib | Arm Label: Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Ibrutinib | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Chlorambucil
C: Arm Label: Treatment Arm A: Ibrutinib and Venetoclax (I+VEN); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Venetoclax, Drug: Ibrutinib (as Subsequent Therapy) | Arm Label: Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb); Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab, Drug: Ibrutinib (as Subsequent Therapy) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Ibrutinib (as Subsequent Therapy); Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN), Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)
D: Arm Label: Arm I (rituximab, bendamustine hydrochloride); Type: ACTIVE_COMPARATOR; Interventions: Drug: Bendamustine Hydrochloride, Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm II (ibrutinib); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment | Arm Label: Arm III (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Bendamustine Hydrochloride; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride) | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Bone Marrow Aspiration; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Bone Marrow Biopsy; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm III (ibrutinib, rituximab)

Answer: C